Case study

AHCL

Anlon Healthcare Limited

Worth a closer look
60Score

Anlon Healthcare Limited (AHCL) Stock Analysis & Case Study

Is AHCL a good buy? The data-driven verdict.

Anlon Healthcare Limited (AHCL) trades at ₹15,on the numbers it worth a closer look, a Downstox Snapshot Score of 60/100.

On the numbers, Anlon Healthcare Limited (AHCL) worth a closer look, a Downstox Snapshot Score of 60/100, weighing fairly valued at 24.5× earnings, ROE of 18.4%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.

Last updated . Data snapshot for research, not investment advice.

AHCL fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield

Market cap
₹773 Cr
Current price
₹15
P/E ratio
24.5×
P/B ratio
3.37×
Book value
₹4
ROCE
20.8%
ROE
18.4%
Piotroski F-Score
3/8

How AHCL ranks against the 2,373 companies in our screener

We do not hold 3-year profit (PAT) growth or 3-year revenue growth figures for AHCL, as of 9 Aug 2026, so those are not ranked here.

Is AHCL overvalued? AHCL P/E vs peers

AHCL trades at 24.5× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.

The bull case for AHCL

  • AHCL's P/E of 24.5x is lower than 54% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
  • AHCL's return on equity of 18.4% ranks in the 80th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
  • AHCL's return on capital employed of 20.8% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.

The bear case & risks

  • AHCL's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.

AHCL Piotroski F-Score: 3/8, how financially strong is it?

3/8

The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AHCL scores 3/8, weak on the financial-strength checks.

AHCL MTF margin & leverage across 6 brokers

Margin Trading Facility lets you buy AHCL with part of the capital. Lower margin % = higher leverage. Rates compared across 6 brokers (no competitor publishes this):

BrokerMargin requiredApprox. leverage
Zerodha50.00%2.0×
Groww33.88%3.0×
Dhan50.00%2.0×
Kotak Neo100.00%1.0×
Pocketful50.00%2.0×
Share IndiaCHEAPEST33.84%3.0×

Compare every broker on the AHCL MTF page.

About Anlon Healthcare Limited: sector, index & market-cap context

Anlon Healthcare Limited (AHCL) is a small-cap NSE-listed company, with a market capitalisation of ₹773 Cr. See more stocks on our screener.

How the AHCL Snapshot Score & forecast are built

The Downstox Snapshot Score is a transparent, rules-based read of Anlon Healthcare Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.

This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.

AHCL analysis, FAQs

Is Anlon Healthcare Limited (AHCL) a good buy?

On the numbers, Anlon Healthcare Limited (AHCL) worth a closer look, a Downstox Snapshot Score of 60/100, weighing fairly valued at 24.5× earnings, ROE of 18.4%. This is a data snapshot for research, not investment advice.

Is AHCL overvalued or undervalued?

AHCL trades at 24.5× earnings, fairly valued versus the ~22× long-run Nifty average.

What is the bull case for AHCL?

AHCL's P/E of 24.5x is lower than 54% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AHCL's return on equity of 18.4% ranks in the 80th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AHCL's return on capital employed of 20.8% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.

What are the risks in AHCL?

AHCL's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.

More on AHCL